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New intravital optical imaging technologies have revolutionized our understanding of mammalian biology and
continue to evolve rapidly. However, there are only a limited number of imaging probes available to date. In this
study, we investigated in mouse models of glioblastoma whether a fluorescent small molecule inhibitor of the
DNA repair enzyme PARP1, PARPi-FL, can be used as an imaging agent to detect glioblastomas in vivo. We
demonstrated that PARPi-FL has appropriate biophysical properties, low toxicity at concentrations used for
imaging, high stability in vivo, and accumulates selectively in glioblastomas due to high PARP1 expression.
Importantly, subcutaneous and orthotopic glioblastoma xenografts were imaged with high contrast clearly
defining tumor tissue from normal surrounding tissue. This research represents a step toward exploring and
developing PARPi-FL as an optical intraoperative imaging agent for PARP1 in the clinic.
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Over the last decade, the DNA repair protein PARP1 has become a
focal point of biomedical research [1–3]. The interest stems from the
observation that human tumors deficient in the DNA repair enzymes
BRCA1 or BRCA2 are often dependent on PARP1 DNA repair
pathways. This makes the tumor cells susceptible to PARP1
inhibitors, a concept known as synthetic lethality. PARP1’s value as
a target for pharmaceutical intervention is reflected in the recent
development of a variety of small molecule PARP1 inhibitors (e.g.
ABT-888, Abbott; AG014699, Pfizer; AZD2281, Astra-Zeneca;
BSI-201, Sanofi-Aventis; MK-4827, Merck).
Originating from the small molecule therapeutic AZD2281
(Olaparib), we synthesized PARPi-FL, a fluorescent small molecule
inhibitor of PARP1 [4,5]. Specifically, the cyclopropane group of
Olaparib was replaced by the green fluorescent BODIPY-FL to
create the PARP1 imaging agent. Binding assays showed that the
affinity of PARPi-FL (12.2 nM) [5] is very close to that of Olaparib(5 nM) [6], indicating that the addition of the BODIPY fluorophore
does not result in an appreciable reduction in binding. This binding was
shown to be rapid and selective to PARP1, similar to the parent compound
Olaparib [4,5]. Additionally, it was shown on a cellular level that the
imaging agent distributes quickly within tumor tissue and efficiently clears
from the regions of low PARP1 expression within minutes [4].
High specific tumor uptake of PARPi-FL in window-chamber
models of human cancer using confocal microscopy [4,7] suggested
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intraoperative detection of cancer in patients. PARPi-FL imaging could
exploit the overexpression of PARP1 in various forms of cancer,
including breast cancer [8–10], melanoma [11], and brain malignancies
[12,13]. The overexpression of PARP1 is particularly apparent in brain
malignancies because of the extremely sparse PARP1 expression in
healthy brain. The high tumor expression and low healthy tissue
expression of PARP1 suggest that it represents a valuable target for
detection and staging of cancer, especially glioblastoma.
The detection and understanding of the genetic and molecular
basis of glioblastoma by non-invasive imaging has advanced
significantly over the last several decades, however progress in
treatment options and survival for glioblastoma patients have been
more limited [14]. While surgery combined with external beam
radiotherapy is initially effective, almost all patients develop
recurrent tumors within a few months. This is in part due to the
diffuse, infiltrative growth of brain tumors, which makes it difficult
to achieve microscopically complete resections. Nevertheless,
several studies have shown that more complete resections prolong
survival [15–17]. Therefore, with the advent of modern intravital
imaging protocols [18], delineation of tumor tissue with a
fluorescent probe in vivo in real time could represent a valuable
tool for operating physicians, allowing more complete removal of
tumor tissue.
In the current study, we hypothesized that PARPi-FL could
ultimately represent a clinically useful intraoperative imaging agent
for glioblastoma. To evaluate PARPi-FL for this use, we designed a
series of experiments to address the following questions: 1) Does
PARPi-FL show toxicity which would prevent its use as an imaging
agent in the clinic? 2) Does PARPi-FL provide sufficient contrast for
in vivo imaging? 3) Is uptake of PARPi-FL in cancer models correlated
to PARP1 expression? 4) Are the kinetics of tumor uptake and
clearance from normal brain compatible with clinical intraoperative
imaging? We not only show that PARPi-FL is a highly selective probe,
but that targeting of PARP1 can be used to identify glioblastomas.
We envision that this imaging agent will ultimately be beneficial in
the clinic by aiding the visualization of glioblastomas during surgery,
helping to achieve more complete tumor resection.
Materials and Methods
Unless otherwise noted, all solvents and reagents were obtained from
Sigma-Aldrich (St. Louis, MO) and did not undergo further
purification. BODIPY-FL succinimidyl ester was purchased from
Life Technologies (Carlsbad, CA). Olaparib (AZD2281) was
purchased from LC Laboratories (Woburn, MA). PARPi-FL was
synthesized as described earlier [5]. All high performance liquid
chromatography (HPLC) purifications were performed on a
Shimadzu UFLC HPLC system equipped with a DGU-20A degasser,
a SPD-M20A UV detector, a LC-20AB pump system, a CBM-20A
communication BUS module, a FRC-10A fraction collector, and a
RF-20A xs fluorescence detector (excitation: 503 nm, emission:
515 nm) using reversed phase columns. A Phenomenex Jupiter
column (5 μm C18, 300 Å, 250 × 10 mm) was used for semi-
preparative purifications (3.5 mL/min, Buffer A: 0.1% trifluoroacetic
acid (TFA) in water, Buffer B: 0.1% TFA in acetonitrile, 10 to 95% B
in 18 min) and a Waters Atlantis T3 column (C18, 5 μm, 4.6 mm ×
250 mm) was used for HPLC purifications (1.0 mL/min, Buffer A:
0.1% TFA in water, Buffer B: 0.1% TFA in acetonitrile, 5 to 95% B
in 17 min).Cell Culture
The human glioblastoma cell lines U87 MG and U251 MG were
generously provided by the laboratory of Dr. Ronald Blasberg
(MSKCC, New York, NY). Both cells lines were grown in Eagle’s
Minimal Essential Medium (MEM), 10% (vol/vol) heat inactivated
fetal bovine serum, 100 IU penicillin, and 100 μg/mL streptomycin,
purchased from the culture media preparation facility at Memorial
Sloan Kettering Cancer Center (MSKCC New York, NY).
Mouse Models
Athymic nude NU/J mice from Jackson Laboratories (Bar Harbor,
Maine) were used for imaging (n = 8) and pharmacokinetic studies (n =
48). Athymic nude CrTac:NCr-Foxn1nu mice from Taconic
Laboratories (Hudson, NY) were used to determine the stability of
PARPi-FL (n = 18). They were further used for orthotopic mouse
models (n = 24). For in vivo toxicology, B6D2F1 mice from Jackson
Laboratories (Bar Harbor, Maine) were used. For subcutaneous
injections, mice were anesthetized with 2% isoflurane gas in 2 L/min
medical air. For orthotopic injections, mice were anesthetized with a
150 mg/kg ketamine and 15 mg/kg xylazine cocktail (10 μL/g). For
all intravenous injections, mice were gently warmed with a heat lamp,
placed on a restrainer, tail sterilized with alcohol pads, and the
injection was placed into a lateral tail vein. All animal experiments
were done in accordance with protocols approved by the Institutional
Animal Care and Use Committee of MSKCC and followed National
Institutes of Health guidelines for animal welfare.
Blood Half-life
The blood half-life of PARPi-FL was calculated by measuring the
ear blood vessel fluorescence. Specifically, the mouse was anesthetized
and placed on a heated stage of a Zeiss Lumar fluorescence dissection
microscope. The ear was secured with tape and a catheter was inserted
into the lateral tail vein. Once set up, time-lapse fluorescence imaging
was performed from pre-injection through 120 minutes post
intravenous injection of PARPi-FL (2.5 mg/kg in 200 μL of
19.5% 1:1 dimethylacetamide (DMAC):Kolliphor, 3.5% DMSO,
77% PBS). Rate capture for time-lapse imaging was 1 image/s until
5 minutes post injection and 12 images/hour for the remaining
115 minutes. Fluorescence intensity of the blood vessel in each image
was quantified using ImageJ 1.47u image processing software. The
blood half-life was calculated using Prism 6.0c (GraphPad Software,
La Jolla, CA).
Hydrophobicity Index Determination
Chemical Hydrophobicity Index (CHI) was determined according
to the procedures reported earlier [19]. Briefly, a series of standards
with known CHIs were analyzed with reverse phase HPLC.
Retention times of the standards along with their known CHIs
were plotted with Prism 6.0c software. A line was fit to the data to
create a calibration curve, which was then used to calculate the CHI
of PARPi-FL based on the HPLC retention time.
In Vitro Toxicity
For MTT-based toxicology, a commercial MTT assay (Sigma
Aldrich, St. Louis, MO) was performed according the manufacturer’s
instructions to measure the amount of living cells through
quantification of the metabolic activity. Specifically, 2.5 × 103 U87
or 5 × 103 U251 glioblastoma cells were seeded per well in 96-well
plates. Plates were incubated at 37 °C, and 24 hours later the media
was aspirated and replaced with varying concentrations of PARPi-FL
Figure 1. Structure of Olaparib precursor and PARPi-FL biophysical properties. (A) Molecular structures of Olaparib and PARPi-FL. Green:
fluorescent BODIPY-FL component of PARPi-FL; (B) Key pharmacokinetic parameters of PARPi-FL and Olaparib in mice; aMenear et al.
2008 [6], bReiner et al. 2012 [5]; cThurber et al. 2013 [4].
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0.1 μM, and 0.03 μM), each in triplicate. The plates were incubated
for 7 days at 37 °C, after which the media was aspirated and replaced
with 10% MTT solution in media. After incubation for 4 hours at
37 °C, an equal amount of MTT solubility solution was added. The
absorbance levels were measured with SpectraMax M5 spectropho-
tometer with SoftMax Pro software, with absorbance at 570 nm and
the background absorbance at 690 nm. Percent survival for U87 and
U251 cells receiving different doses of PARPi-FL or Olaparib were
determined by calculating the percent absorbance readings of their
respective control wells.
Clonogenic proliferation assays were performed as reported earlier
[20]. Briefly, U87 and U251 cells were separately seeded in 6-well
plates (5 × 102 and 1 × 103 cells/well respectively) in 2 mL of
complete media in 6 replicates and allowed to incubate at 37 °C.
After 24 hours the media was replaced with complete media
containing 10 μM PARPi-FL, 10 μM Olaparib, or with drug-free
complete media. Cells were allowed to incubate for 24 hours at
37 °C, after which cells were washed with phosphate-buffered saline
(PBS), and then incubated in drug-free complete media for 14 days.
After incubation, the cells were stained with 0.5% crystal violet stain
for 30 minutes then washed with water. The plates were air dried
overnight and colony numbers were counted.
In Vitro and In Vivo Stability
The in vitro stability was assessed by incubating 10 μM PARPi-FL
in human serum (Sigma-Aldrich, St. Louis, MO) for 0 to 24 hours at
37 °C. At 0 h, 0.25 h, 1 h, 2 h, 4 h, 8 h, 16 h and 24 h the sample
was immediately placed on ice and mixed 1:1 with a solution of
acetonitrile/DMSO (250 μL) and then vigorously vortexed for
30 seconds to precipitate out serum protein. The sample was
centrifuged at 3000 RCF for 3 minutes at 4°C, and the supernatant
collected. This procedure was repeated three times, and the combined
supernatants analyzed by HPLC equipped with fluorescence detector
(Shimadzu RF-20A xs). Concentrations of PARPi-FL in the sampleswere quantified by integrating the PARPi-FL peak using Prism 6.0c
software. In vivo stability was assessed by collecting blood from nude
mice sacrificed at 5 min, 15 min, 30 min, 45 min, and 90 min post
intravenous injection of 2.5 mg/kg PARPi-FL in vehicle solution
stated above. Plasma isolation, analysis, and quantification were done
identically to in vitro serum stability analysis. Additionally, the
fluorescent impurities of the samples were quantified by integrating
the non-PARPi-FL fluorescent peaks.
In Vivo Toxicology
Toxicity was assessed by evaluating mortality, morbidity, clinical
observations, weight, as well as hematological and clinical chemistry
parameters in mice with the help of the Antitumor Assessment core
facility at MSKCC. Four mice were injected intravenously with
2.5 mg/kg of PARPi-FL (in 200 μL of 19.5% 1:1 dimethylacetamide
(DMAC):Kolliphor, 3.5% DMSO, 77% PBS) and 4 mice were
injected with vehicle only. Two days after injection, the mice were
sacrificed. At the time of sacrifice, blood samples were obtained and
hematology analysis was performed with a Hemavet 950FS analyzer
with the following parameters: white blood cell count (WBC), red
blood cell count (RBC), hemoglobin concentration (HB), hematocrit
(HCT), platelet count (PLT). Also at the time of sacrifice, blood
samples were obtained for clinical chemistry analysis performed on a
Beckman Coulter AU680 analyzer with the following parameters:
alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT),
albumin (ALB) and total bilirubin (TBIL).
Surface Fluorescence Imaging
While the cellular pharmacokinetics of PARPi-FL have been
reported in the past [4,7], the macroscopic and organ-specific
distribution has not been investigated so far. In order to determine the
tissue distribution and systemic pharmacokinetics of PARPi-FL, mice
were injected intravenously with the imaging agent, sacrificed at
various time points, and the ex vivo organ epifluorescence was
Figure 2. In vitro toxicity of PARPi-FL and Olaparib. (A,B) Percent of surviving U87 and U251 cells incubated with varying amounts of
PARPi-FL or the parent drug Olaparib for 7 days based on MTT assays; (C) IC50 values obtained from MTT assays for U87 and U251,
treated with PARPi-FL or Olaparib; (D) Representative images of clonogenic assay; (E) Percent surviving U87 cells or (F) U251 cells after
incubation in 10 μM PARPi-FL or 10 μM Olaparib for 24 h based on clonogenic assays.
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implanted subcutaneously (5 × 106 cells in 200 μL 1:1 PBS/
Matrigel (BD Biosciences, San Jose, CA)) in the shoulders of 4 mice
per time point and allowed to grow for approximately two weeks
until the tumors reached 5–10 mm in size. Thereafter, for each
time point 2.5 mg/kg PARPi-FL (in 200 μL 19.5% DMAC:
kolliphor, 3.5% DMSO, 77% PBS) was injected intravenously via
lateral tail vein in 3 mice and vehicle (200 μL of 19.5% DMAC:
kolliphor, 3.5% DMSO, 77% PBS) into one mouse. The cohorts of
mice were then sacrificed at select time points from 5 to
720 minutes post injection. Tumor, brain, and muscle tissues
were harvested post mortem, placed on a petri dish and fluorescence
imaged with a Maestro imaging system. The PARPi-FL emission
spectrum was used to separate out the PARPi-FL signal from
background fluorescence. Regions of interest were drawn around
each organ to calculate the average fluorescence intensity. From this
data, the increase in fluorescence (difference between vehicle
injected mouse organs and PARPi-FL injected organs) was
calculated and plotted with GraphPad Prism 6.0c. For subcutane-
ous blocking studies, U87 cells were implanted and grown in mice
as stated above. The mice were injected with PARPi-FL as stated
above, with the exception that 4 mice were injected with 125 mg/kg
olaparib (in 100 μL of 7.5% DMSO, 12.5% Cremophor, 80%
PBS) prior to injection of PARPi-FL, 4 mice were injected with
vehicle (100 μL of 7.5% DMSO, 12.5% Cremophor, 80% PBS)
prior to injection of PARPi-FL, and 2 mice were injected with
vehicle only. All injections were 30 min prior to the injection of the
imaging agent. Imaging and analysis for the blocking study was
performed with the IVIS spectrum fluorescence imaging system
(PerkinElmer) and Living Image 4.4 software.
Western Blots
For Western blots, tumors, muscle and brain were homogenized in
400 μL of 1x radioimmunoprecipitation assay buffer and 2x MiniComplete Protease Inhibitor Cocktail tablet (Roche, Indianapolis,
IN). The samples were spun at 4 °C at 10,000 rpm for 10 minutes,
and the supernatant was collected. Protein concentration was
measured using a bicinchoninic acid protein assay according to the
manufacturer's instructions (Thermo Scientific, Waltham, MA).
Tumor lysate (30 μg) was loaded onto NuPAGE Novex 4% to 12%
Bis-Tris 1.0-mm gels, and electrophoresis was performed with the
XCell SureLock Mini-Electrophoresis system (both Invitrogen).
Protein was transferred using the iBlot Dry Blotting System to a
nitrocellulose membrane (Invitrogen). The blot was then blocked in
5% nonfat milk for 1 hour, washed with 1× TBS-Tween 20 (Boston
BioProducts, Ashland, MA), and incubated overnight at 4 °C with
1:1000 anti-PARP-1/2 in 5% nonfat milk (Santa Cruz Biotechnol-
ogy). After three 10 minute washes with 1× TBS-Tween 20, blots
were incubated with 1:10,000 goat-anti-rabbit horseradish
peroxidase-conjugated secondary antibody (Jackson ImmunoResearch,
West Grove, PA) at room temperature for 1 hour. After three 10 minute
washes with 1× TBS-Tween 20, blots were incubated with SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific), exposed
for 3 minutes, and then processed with the Kodak (Rochester, NY) X-
OMAT 2000A processor. For β-Actin, the same blot was stripped with
restore WB stripping buffer (Thermo scientific). After three 5 min
washes with TBS-Tween20 the blot was blocked with 5% nonfat
milk in TBS-Tween20 for an hour at room temperature. After
blocking, the blots were incubated for 1 hour at room temperature
with 1:5000 anti-β-Actin (Sigma-Adrich, St Louis, MO) in 5%
nonfat milk (R&D Systems, Minneapolis, MN). After three 10 min
washes with 1 × TBS-Tween 20, blots were incubated with 1:10,000
rabbit-anti-mouse horseradish peroxidase-conjugated secondary
antibody at room temperature for 1 hour. After three 10 min
washes with 1 × TBS-Tween 20, blots were incubated with
SuperSignal West Pico Chemiluminescent Substrate (Thermo
Scientific), exposed for 10 seconds, and then processed with the
Kodak X-OMAT 2000A processor.
in
te
ns
ity
 [A
U]
0
20
40
60
80
100
0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0
PARPi-FL
metabolite
%
 p
ro
du
ct
 a
nd
 m
et
ab
ol
ite
s
60
80
100
40
0 5 15 30 45 90
A
B
time [min]
C
20
0
5
4
3
2
1
0
0 5 15 30 45 90
co
n
ce
n
tra
tio
n 
[µM
]
time [min]
PARPi-FL
metabolitetime [min]
PARPi-FL
metabolite
circu
latio
n tim
e
Figure 3. Metabolic stability of PARPi-FL. (A) Fluorescence-HPLC trace of PARPi-FL (green) and metabolites (red) in mouse blood at
different time points post injection of PARPi-FL (200 μL of 19.5% 1:1 dimethylacetamide (DMAC):Kolliphor, 3.5% DMSO, 77% PBS);
(B) Concentration of PARPi-FL and metabolites at different time points post injection; (C) Percent intact PARPi-FL in mouse blood at
different time points after injection.
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U87 cells (5 × 104 in 20 μL PBS) were implanted into the brains
of mice and allowed to grow for approximately 3 weeks. Tumor-
bearing mice and healthy control mice were injected intravenously
with 2.5 mg/kg of PARPi-FL (in 200 μL 19.5% DMAC:kolliphor,
3.5% DMSO, 77% PBS) and sacrificed 1 hour later. The brains of
the mice were harvested, then imaged and analyzed with IVIS
spectrum fluorescence imaging system (PerkinElmer) and Living
Image 4.4 software. Histology was performed by freezing the brains in
O.C.T. compound (Sakura Finetek USA, Inc., Torrance, CA) on dry
ice. Tissue sections where created by slicing serial 6 μm sections of
the frozen brains. Staining with hematoxylin and eosin (H&E) and
imaging were done with the assistance of the Molecular Cytology
Core Facilities at MSKCC. The size and location of each orthotopic
tumor was documented for each tumor-bearing brain with the
assistance of the Pathology Core Facilities at MSKCC. This protocol
was repeated for orthotopic blocking studies, with the exception that
mice received a dose of either 125 mg/kg olaparib (in 100 μL of
7.5% DMSO, 12.5% Cremophor, 80% PBS) or vehicle (100 μL of
7.5% DMSO, 12.5% Cremophor, 80% PBS) 30 min prior to
injection of PARPi-FL.
Statistical Analysis
Unpaired t-tests were done to determine statistical difference. P b
0.05 was considered statistically significant. Data is presented as
mean ± SEM or mean ± SD.
Results
The molecular structure of PARPi-FL is based on Olaparib
(Figure 1B, [5,6]). The small molecule fluorescent imaging agent is
cleared rapidly from the blood in mice with an alpha half-life of1.2 min and a beta half-life of 88.2 min, resulting in a weighted
blood half-life t1/2 of 24.5 min. The chemical hydrophobicity index
(CHI) is 72.21, which corresponds to a logPCHI of 2.9, a value that is
higher than the CHI of its parent compound Olaparib (CHI = 34.1,
logPCHI = 0.8). And although the hydrophobicity of PARPi-FL
results in a higher plasma protein binding (64.6 ± 5.0 and 99.2 ± 0.1
for olaparib and PARPi-FL, respectively), we were able to show in the
past that PARPi-FL selectively targets PARP1, similar to its parent
compound, both in vitro as well as in vivo [4,5]. The logPCHI of
PARPi-FL compares well with other small molecule drugs, including
drugs that are available in the central nervous system [21].
We investigated the toxicity profile of PARPi-FL in glioblastoma
cell lines using MTT as well as clonogenic assays. For the MTT assays
we incubated cells with either PARPi-FL or Olaparib at concentra-
tions between 30 nM and 0.1 mM for 7 days. In the glioblastoma cell
lines U87 and U251, PARPi-FL has similar toxicity to Olaparib
(Figure 2, A and C). The IC50 of PARPi-FL was calculated to be
slightly lower than Olaparib (27.7 ± 1.3 μM and 23.8 ± 1.3 μM,
respectively, for U87; 8.0 ± 1.2 μM and 5.5 ± 1.2 μM, respectively,
for U251). MTT-based assays indicate that both PARPi-FL and
Olaparib are more toxic to U251 cells than U87 cells (Figure 2, B and
C). The obtained IC50 values of Olaparib are within the range of
those obtained previously for different cell lines (IC50 = 1.0 μM –
33.8 μM [22]), supporting the validity of the results seen here. In
order to further analyze the in vitro toxicity of PARPi-FL, clonogenic
assays were also performed. PARPi-FL and Olaparib demonstrated a
similar reduction in the number of surviving colonies for both U87
and U251 cells (Figure 2, E and F). When tested on U87 cells, both
PARPi-FL and Olaparib decreased the number of surviving colonies
by 20-30%. (P = 0.23, and P = 0.42 compared with vehicle,
respectively, Figure 2E). When tested on U251 cells, both PARPi-FL
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surviving cells (Figure 2F). Normalized to control, the cell survival
rate in PARPi-FL was 35.3% (P b .001) and Olaparib was 46.9%
(P = .013). Given that the results from the in vitro toxicity assessment
indicated similar toxicity levels in PARPi-FL and Olaparib, we next
sought to evaluate the toxicity of PARPi-FL in vivo. Following
injection of 2.5 mg/kg PARPi-FL or vehicle, none of the mice showed
signs of sickness or distress from PARPi-FL based on clinical
observations of behavioral and physical indicators, and all mice
survived until their endpoints (48 h). At the end point of the study, no
hematological or clinical chemistry measurements indicated that
PARPi-FL had immediate adverse effects to the health of the mice
(Supplementary Table S1).
Similar to radioactive tracers, the stability of an imaging agent
in vivo is essential for its use. Therefore, we aimed to determine if
there were any major fluorescent degradation products that could be
observed during imaging. In human serum (37 °C), the drug showed
no degradation over the course of 24 hours (Supplementary Figure
S1). After injection in mice (2.5 mg/kg in 200 μL of 19.5% 1:1
dimethylacetamide (DMAC):Kolliphor, 3.5% DMSO, 77% PBS),
blood samples were obtained between 5 and 90 minutes post
injection and the compound and impurities were quantified using an
HPLC equipped with a fluorescence detector. Throughout the series,
impurity peaks were seen between 8.0 and 14.0 minutes of retention
time, whereas the pure compound peak was detected at 14.3 minutes
(Figure 3A). The concentration of product and impurities at each
time point were calculated by integrating the product or impurities
peaks in their respective time frames, then converting to concentra-
tion by using a calibration curve (Figure 3B). Even after 30 min of
circulation, more than 54.1 ± 5.9 % of the compound is intact
(Figure 3C). More significantly, during the initial uptake phase of
PARPi-FL into tissue (0 min − 5 min), the vast majority of the
compound is intact (80.3%, SEM = 1.6%). Notably, there are more
than 10 metabolite peaks, each of them making up only a small
fraction of the total fluorescent signal. The large number of
metabolites makes the identification of individual small peaks
difficult, particularly at later time points. This indicates that the
cellular uptake and fluorescent signal produced by PARPi-FL and
observed in earlier imaging studies [4,7] likely originates from the
original PARP1 inhibitor, indicating the compound to have a suitable
stability for further investigation.
Ex vivo epifluorescence imaging of PARPi-FL measured by ex vivo
showed that after an initial clearing phase (0 min – 30 min, Figure 4),
PARPi-FL is retained in U87 tumors (Figure 4A) at much higher
levels and longer than healthy brain (Figure 4B) or muscle
(Figure 4C) post intravenous injection. Specifically, at 90 minutes
post intravenous injection, the concentration of PARPi-FL in tumor
(mean AU/px = 20.49, SEM = 3.68) was markedly higher than
muscle (mean AU/px = 3.45, SEM = 0.45) or brain (mean AU/px =
0.13, SEM = 0.10), indicating that PARPi-FL is capable of generating
high contrast images of tumor tissue in the brain. For optical imaging,
a window between 60 minutes and 180 minutes post injection is
ideal. We have shown in earlier works [4,5] that this provides a long
enough time for the imaging agent to accumulate in the nucleus as
well as to clear from the vasculature, extracellular and perinuclear
space, allowing PARP1-specific optical imaging.
Uptake of PARPi-FL by U251 tumors was lower than in U87
tumors, but also markedly higher than of normal brain and muscle
(Figure 5). Western blot analyses (Figure 5C) showed greaterexpression of PARP1 in tumor tissue compared to normal muscle
or brain tissues, correlating to the PARPi-FL signal. The differences in
PARPi-FL uptake between U87 and U251 xenografts could be
influenced by variabilities in vascular permeability, tissue perfusion or
other factors influenced by the tumor microenvironment. In order to
probe the specificity of PARPi-FL uptake in xenografts, we
intravenously injected a 50-fold excess of olaparib into U87
xenograft-bearing mice 30 minutes prior to the injection of PARPi-
FL. This reduced the uptake of the fluorescent imaging agent by 79%
(P = 0.002), confirming that PARPi-FL is targeting PARP1 (Figure 6,
A-B). High resolution fluorescence imaging showed that PARPi-FL
indeed accumulates in cell nuclei, resulting in staining patterns similar
to those observed before (Supplementary Figure 6C, [4,5]).
In addition to subcutaneous xenografts, we used orthotopic mouse
models for PARPi-FL imaging. PARPi-FL was injected into groups of
orthotopic tumor-bearing and healthy mice, which were sacrificed
1 hour post injection for ex vivo imaging of the brains (Figure 7).
Mice bearing orthotopic tumors showed significantly higher uptake of
PARPi-FL than healthy mice injected with the imaging agent
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Figure 5. PARPi-FL tumor accumulation and PARP1 expression. (A) Representative images of tumor, muscle and brain tissue 2 h after
injection of PARPi-FL (200 μL of 19.5% 1:1 DMAC:Kolliphor, 3.5% DMSO, 77% PBS) or vehicle only imaged ex vivo; (B) Fluorescence
quantification of U87 xenograft, U251 xenograft, muscle and brain tissue; (C) PARP1 Western Blot of imaged organs.
Figure 6. PARPi-FL imaging of U87 tumors with and without prior injection of olaparib. (A) Representative white light, fluorescence, and
overlay images of U87 tumor tissues which were injected with either vehicle alone, PARPi-FL (2.5 mg/kg, 200 μL of 19.5% 1:1 DMAC:
Kolliphor, 3.5% DMSO, 77% PBS) or olaparib/PARPi-FL (125 mg/kg olaparib in 100 μL of 7.5% DMSO, 12.5% Cremophor, 80% PBS,
followed 30 minutes later by 2.5 mg/kg PARPi-FL in 200 μL of 19.5% 1:1 DMAC:Kolliphor, 3.5% DMSO, 77% PBS); (B) Fluorescence
quantification of U87 xenografts from panel 6A; (C–E) Fluorescence microscope imaging of tumor tissues in panel 6A, confirming nuclear
uptake of PARPi-FL in non-blocked tumor tissues, but not in the vehicle or Olaparib pre-treatment groups.
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tumors, we were able to suppress the uptake of PARPi-FL in mice
which were injected with olaparib prior to PARPi-FL (Supplementary
Figure S2A). High resolution imaging of a mouse brain bearing an
orthotopic U87 glioblastoma furthermore showed that the uptake of
PARPi-FL in the tumor is nuclear (Supplementary Figure S2), similar
to the uptake patterns observed previously (Figure 6C). In healthy
areas of a brain bearing an orthotopic U87 tumor, no nuclear staining
of the cells was observable. In a two-dimensional non-background
corrected fluorescence intensity profile, tumor-bearing brain tissue
showed a large increase in fluorescence (maximum radiant efficiency =
5.0 × 108) in the area of tumor tissue, as opposed to non-tumor-bearing brain tissue which showed little fluorescence across the length
of the brain (maximum radiant efficiency = 0.5 × 108) and was only
slightly greater than that of background fluorescence (max radiant
efficiency = 0.3 × 108, Figure 7B). Following imaging, the mouse
brains were frozen and histological sections were prepared for H&E
staining. The presence and location was then confirmed to
correspond well with the areas of highest fluorescence intensity
(Figure 7C).
Discussion
The National Cancer Institute estimates that 23,380 adults (12,820
men and 10,560 women) will be diagnosed with brain and other
Figure 7.Orthotopic brain tumor imaging with PARPi-FL. (A) White light, fluorescence, and overlay images of healthy brain and orthotopic
tumor-bearing brain imaged with an IVIS spectrum fluorescence imaging system 1 hour post intravenous injection (200 μL of 19.5% 1:1
DMAC:Kolliphor, 3.5% DMSO, 77% PBS); (B) Profile plot of fluorescence intensity across orthotopic tumor-bearing brain, healthy brain,
and background; (C) H&E stained tumor-bearing brain section from A; (D) High resolution image of tumor shown in C; Radiant efficiency =
(emission light (photons/sec/cm2/str))/(excitation light (mW/cm2)).
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Glioblastoma is a particularly aggressive and invasive form of brain
cancer, and the median survival ranges from 31.9 months for patients
20–29 years of age to only 5.6 months in patients 80 years and older
[23]. One method for improving median survival in glioblastoma
patients is to increase the completeness of tumor tissue resected
during surgery, while not increasing the amount of healthy brain
tissue removed [17,24]. In clinical practice however, the distinction
between malignant growth and healthy brain tissue can be difficult to
make, and the resection of healthy brain increases the incidence of
post-surgical morbidity. To aid surgeons in distinguishing malignant
tissue from normal brain tissue, intraoperative MRI [25] as well as
fluorescence-guided surgery with the use of 5-aminolevulinic acid
[26] have been utilized with some success. Still, progression-free
survival is only modestly improved with the use of these techniques
[25,26]. There is thus a need for better tools for intraoperative
imaging [27,28]. In order to expand the portfolio of potential
clinically relevant intraoperative probes, we investigated the potential
of PARPi-FL to act as an agent to macroscopically delineate between
high PARP1 and low PARP1 expressing tissues. Our aim was to
evaluate the biophysical properties, in vitro and in vivo toxicity,
pharmacokinetics, as well as the potential of PARPi-FL as a
glioblastoma imaging agent in mouse xenograft models.The compound was found to have a toxicity profile comparable to
that of Olaparib, which is currently being used in phase III clinical
trials. The maximum tolerated dose of Olaparib in humans (400 mg,
twice daily) [29] is likely much greater than the dose that would be
required for imaging in human patients using PARPi-FL. In
comparison, intraoperative imaging with indocyanine green requires
one dose of only 500 μg/kg or 35 mg per patient [30]. Similar
concentrations of PARPi-FL are unlikely to induce adverse events.
In vivo organ epifluorescence studies indicate that PARPi-FL
accumulates in U87 subcutaneous xenografts in much higher
concentrations than in muscle or brain tissue, generating signal/
noise ratios in excess of 10/1. We therefore believe that the high
PARPi-FL uptake in glioblastoma could be used to generate a clearly
detectable signal in tumor tissue against normal brain.
In summary, the data presented in this study indicate that the
fluorescent imaging agent PARPi-FL has significant potential for
fluorescence-assisted intraoperative imaging of glioblastoma. Addi-
tionally, because PARP1 is also upregulated in several other
malignancies, PARP1 imaging agents may be useful for the
delineation of not only glioblastoma, but also other primary cancers
[8–11]. We envision their use during intraoperative procedures, non-
invasive tumor diagnostics during endoscopic procedures, and even
analysis of biopsy samples.
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